Literature DB >> 23296986

mTOR is frequently active in GH-secreting pituitary adenomas without influencing their morphopathological features.

Emir Ahmed Sajjad1, Grzegorz Zieliński, Maria Maksymowicz, Łukasz Hutnik, Tomasz Bednarczuk, Paweł Włodarski.   

Abstract

Initiating factors and mechanisms of tumor formation are poorly understood in nonfamilial pituitary adenomas. Alteration of intracellular pathways is an underlying event in numerous neoplasms. Among them, excessive activation of mammalian target of rapamycin (mTOR) pathway and its two main regulators, Akt and Erk, has been detected frequently in solid tumors. This study tests the activation of mTOR pathway in pituitary adenomas and its influence on their morphopathological features. Fifty-three pituitary adenomas were fresh frozen after surgery and analyzed by western blotting using phospho-specific antibodies. The impact of Akt and Erk activation on mTOR pathway was assessed in five primary cultures derived from the excised adenomas using selective kinase inhibitors. Statistical correlations of size, volume, Ki-67 %, Knosp's grading, and somatostatin receptor (SSTR) expression with the activation of mentioned kinases was performed. GHomas showed the highest frequency (71 %) and level of mTOR pathway activity comparing to other adenomas (33 %). No significant correlation was found between mTOR activation and any of the morphopathological features in the studied samples. mTOR kinase phosphorylation was independent of Erk and Akt in primary cultures. Erk activity was significant in all types of adenomas but was the highest in control samples. Its phosphorylation correlated inversely with the Knosp's grading in nonfunctional pituitary adenomas and directly with somatostatin receptor subtype 2 A expression in GHomas. Presented data point to the noteworthy mTOR activity in GHomas. However, the lack of correlation with morphopathological features, its independence of Erk and Akt phosphorylation, and high level of Erk activity in control pituitary necessitate further research for clarifying the role of these pathways in pituitary adenomas.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23296986     DOI: 10.1007/s12022-012-9230-y

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  36 in total

1.  Nelfinavir induces radiation sensitization in pituitary adenoma cells.

Authors:  Jing Zeng; Alfred P See; Khaled Aziz; Saravanan Thiyagarajan; Tarek Salih; Rajendra P Gajula; Michael Armour; Jillian Phallen; Stephanie Terezakis; Lawrence Kleinberg; Kristen Redmond; Russell K Hales; Roberto Salvatori; Alfredo Quinones-Hinojosa; Phuoc T Tran; Michael Lim
Journal:  Cancer Biol Ther       Date:  2011-10-01       Impact factor: 4.742

2.  Glucocorticoid suppresses BDNF-stimulated MAPK/ERK pathway via inhibiting interaction of Shp2 with TrkB.

Authors:  Emi Kumamaru; Tadahiro Numakawa; Naoki Adachi; Hiroshi Kunugi
Journal:  FEBS Lett       Date:  2011-09-19       Impact factor: 4.124

3.  A mutation and expression analysis of the oncogene BRAF in pituitary adenomas.

Authors:  Iain Ewing; Stephen Pedder-Smith; Giulia Franchi; Massimiliano Ruscica; Michelle Emery; Vladimir Vax; Edwin Garcia; Sándor Czirják; Zoltán Hanzély; Blerina Kola; Márta Korbonits; Ashley B Grossman
Journal:  Clin Endocrinol (Oxf)       Date:  2007-03       Impact factor: 3.478

4.  Enhanced protein kinase B/Akt signalling in pituitary tumours.

Authors:  M Musat; M Korbonits; B Kola; N Borboli; M R Hanson; A M Nanzer; J Grigson; S Jordan; D G Morris; M Gueorguiev; M Coculescu; S Basu; A B Grossman
Journal:  Endocr Relat Cancer       Date:  2005-06       Impact factor: 5.678

5.  Effect of everolimus on cell viability in nonfunctioning pituitary adenomas.

Authors:  Maria Chiara Zatelli; Mariella Minoia; Carlo Filieri; Federico Tagliati; Mattia Buratto; Maria Rosaria Ambrosio; Marcello Lapparelli; Massimo Scanarini; Ettore C Degli Uberti
Journal:  J Clin Endocrinol Metab       Date:  2009-12-04       Impact factor: 5.958

Review 6.  The pathophysiology of pituitary adenomas.

Authors:  Dorota Dworakowska; Ashley B Grossman
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2009-10       Impact factor: 4.690

7.  Predicting recurrence of nonfunctioning pituitary adenomas.

Authors:  Tae-Woong Noh; Hyeong Jae Jeong; Mi-Kyung Lee; Tai Seung Kim; Sun Ho Kim; Eun Jig Lee
Journal:  J Clin Endocrinol Metab       Date:  2009-10-09       Impact factor: 5.958

Review 8.  Ki-67 in pituitary neoplasms: a review--part I.

Authors:  Fateme Salehi; Anne Agur; Bernd W Scheithauer; Kalman Kovacs; Ricardo V Lloyd; Michael Cusimano
Journal:  Neurosurgery       Date:  2009-09       Impact factor: 4.654

Review 9.  The role of mTOR in the management of solid tumors: an overview.

Authors:  Alex S Strimpakos; Eleni M Karapanagiotou; M Wasif Saif; Kostas N Syrigos
Journal:  Cancer Treat Rev       Date:  2008-11-14       Impact factor: 12.111

Review 10.  Mammalian target of rapamycin (mTOR) pathway signalling in lymphomas.

Authors:  Elias Drakos; George Z Rassidakis; L Jeffrey Medeiros
Journal:  Expert Rev Mol Med       Date:  2008-02-04       Impact factor: 5.600

View more
  9 in total

1.  PI3K/Akt/mTOR pathway involvement in regulating growth hormone secretion in a rat pituitary adenoma cell line.

Authors:  Carmelina Di Pasquale; Erica Gentilin; Simona Falletta; Mariaenrica Bellio; Mattia Buratto; Ettore Degli Uberti; Maria Chiara Zatelli
Journal:  Endocrine       Date:  2017-10-27       Impact factor: 3.633

2.  Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting.

Authors:  Claudia Pivonello; Roberta Patalano; Domenico Solari; Renata S Auriemma; Federico Frio; Francesca Vitulli; Ludovica F S Grasso; Marialuisa Di Cera; Maria Cristina De Martino; Luigi M Cavallo; Paolo Cappabianca; Annamaria Colao; Rosario Pivonello
Journal:  Endocrine       Date:  2018-07-31       Impact factor: 3.633

Review 3.  Aggressive pituitary tumours and pituitary carcinomas.

Authors:  Gérald Raverot; Mirela Diana Ilie; Hélène Lasolle; Vincent Amodru; Jacqueline Trouillas; Frédéric Castinetti; Thierry Brue
Journal:  Nat Rev Endocrinol       Date:  2021-09-07       Impact factor: 43.330

Review 4.  High-risk pituitary adenomas and strategies for predicting response to treatment.

Authors:  George Kontogeorgos; Eleni Thodou; Robert Y Osamura; Ricardo V Lloyd
Journal:  Hormones (Athens)       Date:  2022-01-21       Impact factor: 2.885

Review 5.  The Treatment of Refractory Pituitary Adenomas.

Authors:  Congxin Dai; Xiaohai Liu; Wenbin Ma; Renzhi Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2019-05-29       Impact factor: 5.555

6.  Lineage-dependent role of miR-410-3p as oncomiR in gonadotroph and corticotroph pituitary adenomas or tumor suppressor miR in somatotroph adenomas via MAPK, PTEN/AKT, and STAT3 signaling pathways.

Authors:  Tomasz M Grzywa; Klaudia Klicka; Beata Rak; Dawid Mehlich; Filip Garbicz; Grzegorz Zieliński; Maria Maksymowicz; Emir Sajjad; Paweł K Włodarski
Journal:  Endocrine       Date:  2019-06-04       Impact factor: 3.633

Review 7.  Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors.

Authors:  Tae Nakano-Tateno; Kheng Joe Lau; Justin Wang; Cailin McMahon; Yasuhiko Kawakami; Toru Tateno; Takako Araki
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-26       Impact factor: 5.555

Review 8.  Targeting Aggressive Pituitary Adenomas at the Molecular Level-A Review.

Authors:  Benjamin Voellger; Zhuo Zhang; Julia Benzel; Junwen Wang; Ting Lei; Christopher Nimsky; Jörg-Walter Bartsch
Journal:  J Clin Med       Date:  2021-12-27       Impact factor: 4.241

Review 9.  The PI3K/Akt Pathway in Tumors of Endocrine Tissues.

Authors:  Helen Louise Robbins; Angela Hague
Journal:  Front Endocrinol (Lausanne)       Date:  2016-01-11       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.